ClinicalTrials.gg
TerminatedNCT03742973Updated Oct 14, 2020Results posted

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

A Phase 2 interventional study of Baricitinib and Placebo in Primary Biliary Cholangitis, sponsored by Eli Lilly and Company. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to enrollment futility.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
62nd of 65
2 · median 46
Started
2019
with 1 other
Phase 2
34 of 83
2 open now
Registered
46th of 83
by date

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 62nd largest by enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2019, is one of 34 in phase 2, and was the 46th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).

03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • Janus kinase inhibitor
  • JAK
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of PBC (consistent with American Association for the Study of Liver Disease (AASLD) and European Association for Study of the Liver (EASL) Practice Guidelines; as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:

    • History of elevated Alkaline Phosphatase (ALP) levels for at least 6 months
    • Positive antimitochondrial antibodies titer
    • Liver consistent with PBC
  • Have ALP ≥1.67 x but ≤6 x Upper Limit Normal (ULN).
  • Taking UDCA for at least 52 weeks (stable dose for at least 12 weeks) prior to Week 0, or have previously taken, but are intolerant (in the opinion of the investigator) to UDCA and have not received UDCA for at least 12 weeks prior to Week 0.
  • Nonpregnant, nonbreastfeeding female participants of .

Exclusion criteria

Exclusion Criteria:

  • History or presence of other concomitant liver diseases including:

    • virus (HCV) infection
    • virus (HBV) infection
    • Primary sclerosing cholangitis
    • Alcoholic liver disease
    • liver disease other than PBC, such as overlap hepatitis
    • Nonalcoholic steatohepatitis
    • Gilbert's syndrome
  • Presence of clinical complications of PBC or hepatic decompensation, including:

    • Liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score ≥15
    • Portal hypertension with complications, including known gastric or esophageal varices, ascites, history of variceal bleeds or related therapeutic or prophylactic interventions (e.g., beta blockers, insertion of variceal bands or transjugular intrahepatic portosystemic shunt), or hepatic encephalopathy
    • Cirrhosis, including history or presence of one or more of the following:

      • spontaneous bacterial peritonitis
      • hepatocellular carcinoma
    • Hepatorenal syndrome (type I or II)
  • Have an estimated (eGFR) based on the most recent available serum creatinine of \<90 milliliters/minute/1.73 m2.
  • Have screening (ECG) abnormalities that in the opinion of the investigator or the sponsor are clinically significant and indicate an unacceptable risk for the participant's participation in the study.
  • Have experienced any of the following within 12 weeks of screening: myocardial infarction, unstable ischemic heart disease, stroke, or Stage III/IV heart failure.
  • Have a history of venous thromboembolism (VTE) (deep vein thrombosis/pulmonary embolism [DVT/PE]).
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking product or interfere with the interpretation of data.
  • Have a current or recent (\<4 weeks prior to randomization) clinically serious infection or any other active or recent infection that, in the opinion of the investigator, would pose an unacceptable risk to the participant if participating in the study.
  • Have had symptomatic herpes zoster infection within 12 weeks prior to randomization.
  • Have active tuberculosis (TB) disease determined on the basis of a positive medical history, physical examination, or chest radiography (per local standard of care) or latent TB infection (LTBI).
  • Have any of the following specific abnormalities based on screening central lab test results:

    • \<10 grams per deciliter (100.0 grams per liter)
    • (ALT) >3 x
    • aspartate aminotransferase (AST) >3 x ULN
    • alkaline phosphatase (ALP) >6 x ULN
    • Total level (TBL) >ULN
    • Creatine phosphokinase (CPK) > ULN
    • Serum albumin \< lower limit of normal (LLN)
    • of Prothrombin Time (INR) > ULN
    • Total white blood cell (WBC) count \<LLN
    • (ANC) \<LLN
    • Lymphocyte count \<LLN
    • (thrombocyte) count \<LLN
  • Are receiving unstable treatment for pruritus within 6 weeks prior to Week 0.
  • Have been treated with systemic (oral or parenteral) within 6 weeks prior to Week 0.
  • Have received biologic treatments for an immunologic disease within 4 weeks of screening.
  • Have received a Janus kinase (JAK) inhibitor.
  • Have received obeticholic acid.
  • Have received fenofibrate or other fibrates for the treatment of PBC.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Baricitinib Cohort A

    Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.

    Drug: Baricitinib

  • Placebo comparator
    Placebo Cohort A

    Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.

    Drug: Placebo

  • Experimental
    Baricitinib Cohort B

    Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.

    Drug: Baricitinib

  • Placebo comparator
    Placebo Cohort B

    Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.

    Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Alkaline Phosphatase (ALP)

    Change from baseline in Alkaline Phosphatase (ALP)

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants With Alkaline Phosphatase (ALP) <1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than ULN

    Percentage of participants with alkaline phosphatase (ALP) \<1.67 x Upper Limit of Normal (ULN) (and at least 15% decrease from baseline) and total bilirubin level less than ULN.

    Time frame: Week 12

  2. Change From Baseline in Itch Numeric Rating Scale (NRS)

    Change from baseline in itch NRS. The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 7 days.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Fatigue NRS

    Change from baseline in fatigue NRS. The Fatigue NRS is a single-item, patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Overall severity of a participant's fatigue is indicated by selecting the number that describes the worst level of fatigue during the past 7 days.

    Time frame: Baseline, Week 12

07

Results

Posted Oct 14, 2020
Limitations and caveats
Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.

Participant flow

Participant flow — Overall Study
MilestoneBaricitinib Cohort APlacebo Cohort A
Started00
Completed00
Not completed00

Outcome measures

PrimaryChange From Baseline in Alkaline Phosphatase (ALP)

Change from baseline in Alkaline Phosphatase (ALP)

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Alkaline Phosphatase (ALP) <1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than ULN

Percentage of participants with alkaline phosphatase (ALP) \<1.67 x Upper Limit of Normal (ULN) (and at least 15% decrease from baseline) and total bilirubin level less than ULN.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Itch Numeric Rating Scale (NRS)

Change from baseline in itch NRS. The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 7 days.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Fatigue NRS

Change from baseline in fatigue NRS. The Fatigue NRS is a single-item, patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Overall severity of a participant's fatigue is indicated by selecting the number that describes the worst level of fatigue during the past 7 days.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

Adverse events

Collected over Up to 6 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib Cohort A———
Placebo Cohort A———

Baseline characteristics

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.

Age, Categorical
Age, CategoricalPlacebo Cohort A.Baricitinib Cohort ATotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Sex: Female, Male
Sex: Female, MalePlacebo Cohort A.Baricitinib Cohort ATotal
Female———
Male———
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)Placebo Cohort A.Baricitinib Cohort ATotal
Hispanic or Latino———
Not Hispanic or Latino———
Unknown or Not Reported———
Race (NIH/OMB)
Race (NIH/OMB)Placebo Cohort A.Baricitinib Cohort ATotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of EnrollmentPlacebo Cohort A.Baricitinib Cohort ATotal
Baseline in ALP
Baseline in ALP(microgram/Liter (u/L))Placebo Cohort A.Baricitinib Cohort ATotal
08

Study locations

12 sites
  • Southern California GI and Liver Centers (SCLC)
    Coronado, California 92118, United States
  • University of California, Davis - Health Systems
    Sacramento, California 95817, United States
  • University of Colorado School of Medicine
    Aurora, Colorado 80045, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • The Institute for Digestive Health and Liver Disease at Mercy
    Baltimore, Maryland 21202, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • NYU Langone
    New York, New York 10016, United States
  • UH Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Klinical Investigations Group, LLC
    San Juan, 00909, Puerto Rico
  • University of Puerto Rico, Medical Sciences Campus
    San Juan, 00936, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Sep 2019, 5 months.

Results were first posted in Oct 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2018
First posted
Nov 15, 2018
StartActual
Mar 28, 2019
Primary completionActual
Sep 26, 2019
CompletionActual
Sep 26, 2019
Results first posted
Oct 14, 2020
Last update
Oct 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03742973
Responsible party
Sponsor
First posted
Nov 15, 2018
Start date
Mar 28, 2019
Primary completion
Sep 26, 2019
Completion
Sep 26, 2019
Results posted
Oct 14, 2020
Last update
Oct 14, 2020

Study contacts

Call 1-877-CTILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion